Literature DB >> 3159442

Acceleration of fibrinolysis by the N-terminal peptide of alpha 2-plasmin inhibitor.

S Kimura, T Tamaki, N Aoki.   

Abstract

When blood plasma containing the NH2-terminal 12-residue peptide (N-peptide) of alpha 2-plasmin inhibitor (alpha 2PI; alpha 2-antiplasmin) was clotted in the presence of calcium ions, the N-peptide and alpha 2PI were cross-linked to fibrin by activated coagulation factor XIII. The amount of N-peptide cross-linked to fibrin was proportional to the concentration of N-peptide present in plasma. On the other hand, the amount of alpha 2PI cross-linked to fibrin was decreased by the presence of N-peptide, and the decrease was in reverse relationship to the increase of cross-linking of N-peptide. Spontaneous fibrinolysis or fibrinolysis induced by tissue plasminogen activator was accelerated by the presence of N-peptide, and the acceleration was dependent on the concentrations of N-peptide and directly proportional to inhibition of alpha 2PI cross-linking exerted by N-peptide. The acceleration was more pronounced when the clot was compacted by platelet-mediated clot retraction or by a squeeze. Fibrinolysis of an alpha 2PI-deficient or a factor XIII-deficient plasma clot was not accelerated by N-peptide. These findings were substantiated in a purified system and support the previous proposal that alpha 2PI is cross-linked to fibrin at the glutamine residue that is next to the NH2-terminus of alpha 2PI, and this factor XIII-mediated cross-linking of alpha 2PI is significant in inhibition of physiologically occurring endogenous fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159442

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Guava extract (Psidium guajava) alters the labelling of blood constituents with technetium-99m.

Authors:  P R C Abreu; M C Almeida; R M Bernardo; L C Bernardo; L C Brito; E A C Garcia; A S Fonseca; M Bernardo-Filho
Journal:  J Zhejiang Univ Sci B       Date:  2006-06       Impact factor: 3.066

2.  Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.

Authors:  J Mimuro; S Kimura; N Aoki
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

3.  Affinity-based release of glial-derived neurotrophic factor from fibrin matrices enhances sciatic nerve regeneration.

Authors:  Matthew D Wood; Amy M Moore; Daniel A Hunter; Sami Tuffaha; Gregory H Borschel; Susan E Mackinnon; Shelly E Sakiyama-Elbert
Journal:  Acta Biomater       Date:  2008-12-06       Impact factor: 8.947

Review 4.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

5.  Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease.

Authors:  Satish Singh; Sofiyan Saleem; Guy L Reed
Journal:  Front Cardiovasc Med       Date:  2020-12-23

Review 6.  Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

Authors:  Nikoletta Pechlivani; Katherine J Kearney; Ramzi A Ajjan
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

7.  Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis.

Authors:  William P Sheffield; Louise J Eltringham-Smith; Sharon Gataiance; Varsha Bhakta
Journal:  BMC Biotechnol       Date:  2009-03-03       Impact factor: 2.563

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.